Clinical trials in chronic obstructive pulmonary disease (COPD) advancing effective combination treatments

Impact: Health and wellbeing, Economic


Our research has led to a step change in care, from simple inhaled therapies to more effective, simpler to use, combination dual and triple therapies. Our industrial collaborations delivered a new dual therapy, and three new triple therapies. Most recently, the first triple combination therapy to be approved in Europe for COPD. These treatments have reduced known risks of multiple single inhaler use and brought more effective treatment options to patients globally. Notably, AstraZeneca‘s dual inhaler, approved by the European Medicines Agency (EMA) and US Food and Drug Administration (FDA), is available in 25 countries. UoM research has been included in the National Institute for Health and Care Excellence (NICE) guidance evidence reviews, cited in Australian and New Zealand Clinical Guidelines and in internationally renowned Global Initiative for Chronic Obstructive Lung Disease (GOLD) Strategy documents.
Impact date1 Aug 201331 Dec 2020
Category of impactHealth and wellbeing, Economic
Impact levelAdoption

Research Beacons, Institutes and Platforms

  • Lydia Becker Institute